(secondQuint)Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma.

 This is a Phase 2, two-arm, randomized, placebo-controlled, double-blind, multicenter study of relapsed/refractory multiple myeloma patients who have received at least two prior therapies, including a proteasome inhibitor and an IMiD.

 Patients who meet all the eligibility criteria will be randomized to one of two blinded treatment arms: - selinexor + carfilzomib + dexamethasone - placebo + carfilzomib + dexamethasone.

 Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma@highlight

Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis(R)) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

